Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6826 to 6840 of 7707 results

  1. Intravaginal sling for stress urinary incontinence

    Discontinued [GID-IP267]

    Interventional procedures guidance
    Discontinued

  2. Extra corporeal membrane oxygenation for acute heart failure in children

    Discontinued [GID-IP1153]

    Interventional procedures guidance
    Discontinued

  3. Emphysema - inhaled alpha-1 antitrypsin [ID1200]

    Discontinued [GID-TA11179]

    Technology appraisal guidance
    Discontinued

  4. Ramucirumab for untreated HER2-negative metastatic gastric or gastro-oesophageal junction cancer [ID1373]

    Discontinued [GID-TA11120]

    Technology appraisal guidance
    Discontinued

  5. Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies [ID1455]

    Discontinued [GID-TA10356]

    Technology appraisal guidance
    Discontinued

  6. Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]

    Discontinued [GID-TA10474]

    Technology appraisal guidance
    Discontinued

  7. Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab [ID1487]

    Discontinued [GID-TA10437]

    Technology appraisal guidance
    Discontinued

  8. Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy [ID1147]

    Discontinued [GID-TA10343]

    Technology appraisal guidance
    Discontinued

  9. Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]

    Discontinued [GID-TA10473]

    Technology appraisal guidance
    Discontinued

  10. Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

    Discontinued [GID-TA10320]

    Technology appraisal guidance
    Discontinued

  11. Carotuximab with pazopanib for treating advanced angiosarcoma [ID1503]

    Discontinued [GID-TA10401]

    Technology appraisal guidance
    Discontinued

  12. Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]

    Discontinued [GID-TA10627]

    Technology appraisal guidance
    Discontinued

  13. Masitinib for treating relapsed or refractory peripheral T-cell non-Hodgkin lymphoma [ID1125]

    Discontinued [GID-TA11173]

    Technology appraisal guidance
    Discontinued

  14. Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma [ID1470]

    Discontinued [GID-TA10354]

    Technology appraisal guidance
    Discontinued

  15. Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]

    Discontinued [GID-TA10480]

    Technology appraisal guidance
    Discontinued